The ability to transorm biologically exogenous daunomycinone, 13-dihydrodaunomycinone, aklavinone, 7-deoxyaklavinone, epsilon-rhodomycinone, epsilon-isorhodomycinone and epsilon-pyrromycinone was studied in submerged cultures of the following strains: wild Streptomyces coeruleorubidus JA 10092 (W1) and its improved variants 39-146 and 84-17 (type P1) producing glycosides of daunomycinone and of 13-dihydrodaunomycinone, together with epsilon-rhodomycinone, 13-dihydrodaunomycinone and 7-deoxy-13-dihydrodaunomycinone; in five mutant types of S. coeruleorubidus (A, B, C, D, E) blocked in the biosynthesis of glycosides and differing in the production of free anthracyclinones; in the wild Streptomyces galilaeus JA 3043 (W2) and its improved variant G-167 (P2) producing glycosides of epsilon-pyrromycinone and of aklavinone together with 7-deoxy and bisanhydro derivatives of both aglycones; in two mutant types S. galilaeus (F and G) blocked in biosynthesis of glycosides and differing in the occurrence of anthracyclinones. The following bioconversions were observed: daunomycinone leads to 13-dihydrodaunomycinone and 7-deoxy-13-dihydrodaunomycinone (all strains); 13-dihydrodaunomycinone leads to 7-deoxy-13-dihydrodaunomycinone (all strains); daunomycinone or 13-dihydrodaunomycinone leads to glycosides of daunomycinone and of 13-dihydrodaunomycinone, identical with metabolites W1 and P1 (type A), or only a single glycoside of daunomycinone (type E); aklavinone leads to epsilon-rhodomycinone (types A and B); aklaviinone leads to 7-deoxyaklavinone and bisanhydroaklavinone (type C); epsilon-rhodomycinone leads to zeta-rhodomycinone (types C, E); epsilon-rhodomycinone leads to glycosides of epsilon-rhodomycinone (types W2, P2); epsilon-isorhodomycinone leads to glycosides of epsilon-isorhodomycinone (types W2, P2); epsilon-pyrromycinone leads to a glycoside of epsilon-pyrromycinone (types W1, P1). 7-Deoxyaklavinone remained intact in all tests. Exogenous daunomycinone suppressed the biosynthesis of its own glycosides in W1 and P1; it simultaneously increased the production of epsilon-rhodomycinone in P1.

Zobrazit více v PubMed

J Antibiot (Tokyo). 1975 Oct;28(10):838-40 PubMed

J Antibiot (Tokyo). 1977 Jul;30(7):619-21 PubMed

Blood. 1972 May;39(5):637-43 PubMed

J Pharmacol Exp Ther. 1976 Jun;197(3):681-6 PubMed

Folia Microbiol (Praha). 1979;24(2):128-35 PubMed

Z Allg Mikrobiol. 1977;17(1):47-50 PubMed

J Pharmacol Exp Ther. 1971 Jun;177(3):567-72 PubMed

J Antibiot (Tokyo). 1977 Jul;30(7):622-4 PubMed

Biochemistry. 1976 Sep 21;15(19):4139-45 PubMed

Folia Microbiol (Praha). 1977;22(5):321-8 PubMed

Antibiotiki. 1977 Jan;22(1):37-41 PubMed

Biochem Biophys Res Commun. 1977 Jan 24;74(2):331-5 PubMed

J Antibiot (Tokyo). 1977 May;30(5):432-4 PubMed

Folia Microbiol (Praha). 1978;23(3):246-8 PubMed

Folia Microbiol (Praha). 1978;23(4):255-60 PubMed

Z Allg Mikrobiol. 1966;6(5):361-5 PubMed

J Antibiot (Tokyo). 1976 Sep;29(9):966-8 PubMed

J Antibiot (Tokyo). 1977 Jul;30(7):613-5 PubMed

Folia Microbiol (Praha). 1978;23(4):249-54 PubMed

J Antibiot (Tokyo). 1977 Aug;30(8):649-54 PubMed

J Antibiot (Tokyo). 1976 Nov;29(11):1199-202 PubMed

Folia Microbiol (Praha). 1977;22(2):139-59 PubMed

Folia Microbiol (Praha). 1977;22(4):275-85 PubMed

J Antibiot (Tokyo). 1977 Jan;30(1):50-8 PubMed

Folia Microbiol (Praha). 1973;18(6):524-6 PubMed

Streptomycetes producing daunomycin and related compounds: do we know enough about them after 25 years?

Microbial transformation of semisynthetic derivatives of daunomycinone modified in ring A

Intra- and interspecific cosynthetic activity of mutants of Streptomyces coeruleorubidus and Streptomyces galilaeus impaired in the biosynthesis of anthracyclines